Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk…
If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as -DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional imaging.Proven track record of -DCFPyL…